| Name | B-lymphocyte antigen CD20 | ||
| UniProt ID | CD20_HUMAN | ||
| Gene Name | MS4A1 | ||
| Gene ID | 931 | ||
| Synonyms |
MS4A1, B1, Bp35, CD20, CVID5, FMC7, LEU-16, S7
|
||
| Sequence |
MTTPRNSVNGTFPAEPMKGPIAMQSGPKPLFRRMSSLVGPTQSFFMRESKTLGAVQIMNG
LFHIALGGLLMIPAGIYAPICVTVWYPLWGGIMYIISGSLLAATEKNSRKCLVKGKMIMN SLSLFAAISGMILSIMDILNIKISHFLKMESLNFIRAHTPYINIYNCEPANPSEKNSPST QYCYSIQSLFLGILSVMLIFAFFQELVIAGIVENEWKRTCSRPKSNIVLLSAEEKKEQTI EIKEEVVGLTETSSQPKNEEDIEIIPIQEEEEEETETNFPEPPQDQESSPIENDSSP |
||
| Pathway Map | MAP LINK | ||
| T.C. Number | 1.A.37.1.1 | ||
| KEGG ID | hsa931 | ||
| TTD ID | T73215 | ||
| Pfam | PF03021; PF04103 | ||
| Pair Name | Silibinin, Doxorubicin | |||
| Phytochemical | Silibinin | |||
| Drug | Doxorubicin | |||
| Disease Info | [ICD-11: 2C12] | Hepatocellular carcinoma | Investigative | |
| Regulate Info | Up-regulation | B-lymphocyte antigen CD20 | Expression | |
| Result | Inhibitory effects of Silibinin combined with doxorubicin in hepatocellular carcinoma; an in vivo study | |||
